Boehringer Ingelheim: Pulmonary Disease, Chronic Obstructive trials

The registry lists 236 Pulmonary Disease, Chronic Obstructive studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 124 have results posted.

Phase 1 7Phase 2 33Phase 3 81Phase 4 32No phase 83(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.CompletedNCT00388882Phase 4
• General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and TreatmentCompletedNCT00319813
• A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00292448Phase 2
• Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00281567Phase 3
• Spiriva® Assessment of FEV1 (SAFE)CompletedNCT00277264Phase 3
• Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different SeverityCompletedNCT00274573Phase 3
• A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.CompletedNCT00274560Phase 3
• Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00274547Phase 3
• A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.CompletedNCT00274534Phase 3
• Tiotropium (Spiriva) Rehabilitation StudyCompletedNCT00274521Phase 3
• Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD PatientsCompletedNCT00274508Phase 3
• Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00274092Phase 3
• SPIRIVA in Ususal CareCompletedNCT00274079Phase 4
• Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of SpirivaCompletedNCT00274066Phase 3
• Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPDCompletedNCT00274053Phase 3
• Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPDCompletedNCT00274040Phase 3
• Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)CompletedNCT00274027Phase 3
• Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory DisordersCompletedNCT00274014Phase 3
• Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung ClinicsCompletedNCT00268866
• Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.CompletedNCT00267917Phase 4
• 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPDCompletedNCT00240435Phase 3
• Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00239499Phase 4
• 12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPDCompletedNCT00239473Phase 3
• Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPDCompletedNCT00239460Phase 3
• Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPDCompletedNCT00239447Phase 3
• A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00239434Phase 3
• A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00239421Phase 4
• Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).CompletedNCT00239408Phase 4
• Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD PatientsCompletedNCT00157235Phase 3
• Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00153075Phase 4
• Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of AsthmaCompletedNCT00152984Phase 4
• A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00144326Phase 3
• 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)CompletedNCT00144196Phase 4
• High Dose Trial in COPDCompletedNCT00128440Phase 2
• Dose Finding Study in COPDCompletedNCT00122434Phase 2
• Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary DiseaseCompletedNCT00106821Phase 4